Amgen drug shows promise
From Times Wire Services
Amgen Inc. said its experimental osteoporosis drug denosumab strengthened bones and reduced spinal fractures in men undergoing treatment for prostate cancer in a clinical trial.
In the three-year study, 1,400 men taking denosumab had improved bone density and half as many spinal fractures compared with a placebo, the Thousand Oaks company said.
